The FDA is requiring all GLP-1 drug labels to carry a NAION warning, though trial and observational data on the eye-stroke risk are mixed.
The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed ‘fastest growing company in history.’
In 2024, OpenAI CEO Sam Altman predicted that a single entrepreneur using AI would generate a business worth more than one billion dollars. The L.A. entrepreneur Matthew Gallagher apparently is boasting that his telehealth startup MEDVi is among the first companies to make good on that prediction. On LinkedIn, he has called the firm, which…
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
The Pharma 50 has a new company sitting at the top: Eli Lilly, which last year was in the ninth slot. The next question is how long it can stay there, because pharma sector leadership is, historically, something of a revolving door. Right now, Lilly’s lead is razor thin. Just $170 million separated Eli Lilly’s…
Study finds GLP-1 benefits fade two years after stopping medication
A large analysis of previous studies has found that patients who stop taking weight loss medications will see the beneficial effects disappear within two years, causing weight and health issues to reappear. Researchers reviewed data on 9,341 obese or overweight patients treated across 37 studies with 18 different weight-loss medications, finding that they gained approximately…
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
Treating obesity may directly improve psoriatic arthritis outcomes, according to Phase 3b data released Wednesday by Eli Lilly. In the TOGETHER-PsA trial, patients receiving both Zepbound (tirzepatide) and Taltz (ixekizumab) showed a 64% relative improvement in arthritis disease activity compared to those on Taltz alone. The findings suggest obesity treatment directly improves psoriatic arthritis disease…
Novo Nordisk launches first GLP-1 pill for obesity, but Lilly may dominate the oral market eventually
GLP-1 drugs have become the hottest drug class in a generation, driven by an obesity epidemic affecting 40% of American adults and linked to diabetes, heart disease and a growing list of other conditions. But there’s a catch: up to two-thirds of adults report some level of needle fear. A 2022 PLOS One international survey…
Eli Lilly announces Q3 results, $3 billion new site, plans for oral GLP-1 approval
Quarter 3 results Eli Lilly reported a 54% increase in revenue in the third quarter, rising to $17.60 billion in 2025 from $11.439 billion in 2024, which the company largely credited to sales of Mounjaro and Zepbound, the company’s GLP-1 agonist weight-loss treatments. Mounjaro revenue saw a 109% increase in revenue from the third quarter…
Lilly is set to lead pharma in 2026, but can it justify an $800B valuation?
Eli Lilly is on track to overtake pharma rivals and claim the industry’s top spot by late 2026, completing one of the most dramatic repositionings in Big Pharma’s recent history. Aggressive and base scenarios place Lilly’s rise to the number one slot in 2026, while a conservative prediction forecasts that the firm will do so…
Novo Nordisk board chair and members quit after disagreement on board membership
Once so valuable its market capitalization eclipsed that of its home country of Denmark, pharmaceutical giant Novo Nordisk is now showing signs of strain. Most recently, several members of Novo Nordisk’s board of directors quit after failing to reach an agreement with the Novo Nordisk Foundation, the firm’s controlling shareholder (via Novo Holdings), on the…
Trump’s $150 Ozempic vow hits Novo, Lilly, even as Oz says ‘we have not negotiated those yet’
It took just one off-hand comment during a White House event about fertility treatments for President Trump to temporarily wipe tens of billions from the market cap of the world’s leading obesity drugmakers. Trump’s vow Thursday to bring Ozempic down to $150 per month, calling it “the fat-loss drug,” sent Novo Nordisk shares down 6.3%…
Novo Nordisk lays off dozens of US employees at NC plant
Novo Nordisk has laid off dozens of employees at its plant in North Carolina, an analysis of LinkedIn posts by Reuters found. The layoffs come after the company announced a plan to cut 9,000 jobs globally in an effort to compete with Eli Lilly last month. The exact number of layoffs at the Clayton plant…
Novo Nordisk to cut 9,000 jobs globally to compete in GLP-1 market
Novo Nordisk, the manufacturer of Ozempic, announced a plan to reduce its global workforce by approximately 9,000 positions today. Around 5,000 positions are expected to be cut in Denmark. This will reduce the company’s workforce from its current 78,400 positions to approximately 69,400. The company’s stock has fallen about 58% over the past year as…
Revised time series model forecasts Lilly’s Mounjaro sales to triple in 2024
Eli Lilly is experiencing meteoric growth in 2024, driven by surging demand for its metabolic therapies. In the first quarter, Lilly’s revenue jumped 26% year-over-year to $8.77 billion, propelled by strong sales of diabetes drug Mounjaro and weight loss treatment Zepbound Lilly also significantly raised its full-year 2024 outlook. The company now expects revenue in…












